Lab guide · Mitochondrial compounds
What Is SS-31? Mitochondria-Targeted Peptide Research Overview
What is SS-31? It is a synthetic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2, also called elamipretide, that concentrates in the inner mitochondrial membrane and binds cardiolipin. This guide covers its structure, the cardiolipin mechanism reported in the original studies, and its unusual regulatory position among research peptides.
Key takeaways
- SS-31 is a four-residue peptide, D-Arg-Dmt-Lys-Phe-NH2, with the formula C32H49N9O5 and a molecular weight of 639.8 g/mol.
- It carries a 3+ net charge and an alternating aromatic-cationic motif, and it accumulates in the inner mitochondrial membrane.
- Birk et al. (2013) reported high-affinity binding to cardiolipin and inhibition of cytochrome c peroxidase activity in ischaemia models.
- In September 2025 the FDA granted accelerated approval to an elamipretide medicine for Barth syndrome; research-grade SS-31 is a different, unapproved reagent.
What is SS-31?
So, what is SS-31? SS-31 is a synthetic tetrapeptide of the Szeto-Schiller family, designed around an alternating cationic-aromatic motif. It is also known as elamipretide, MTP-131 or Bendavia. A 2014 review describes it as having a 3+ net charge and as selectively binding cardiolipin (PMC).
Unusually for a research peptide, an elamipretide medicine now has a regulatory approval in one jurisdiction. That is covered below, and it does not apply to research-grade SS-31.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Value |
|---|---|
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2′,6′-dimethyltyrosine) |
| Length | 4 residues, C-terminal amide |
| Molecular formula | C32H49N9O5 |
| Molecular weight | 639.8 g/mol (average); 639.386 Da monoisotopic, calculated |
| PubChem CID | 11764719 |
| Net charge | 3+ at physiological pH |
The formula, mass and sequence match the PubChem record for elamipretide. Two non-standard features matter analytically: the D-arginine at position 1 and the dimethyltyrosine at position 2, which are not found in natural proteins. A mass is the same for an L-isomer, so identity depends on chromatography as well as mass.
Discovery and research history
Hazel Szeto and Peter Schiller developed the SS peptides, and Szeto has described how the compounds were discovered serendipitously, noting that it was “highly unexpected” for a 640 Da, highly polar, triply charged peptide to cross membranes and concentrate in mitochondria (Szeto, 2014).
The cardiolipin mechanism was identified later. Birk et al. (2013, J Am Soc Nephrol) used a polarity-sensitive fluorescent analogue to show that SS-31 binds cardiolipin with high affinity.
Mechanism: cardiolipin binding
Targeting the inner membrane
Cardiolipin is an anionic phospholipid confined to the inner mitochondrial membrane and required for cristae formation. The positive charges of SS-31 interact electrostatically with the phosphate head groups, aligning the aromatic residues in the hydrophobic acyl-chain region, at a 1:1 molar ratio ({A(“https://pmc.ncbi.nlm.nih.gov/articles/PMC3976620/”,”PMC”)}).
Reported consequences
In the 2013 study, the SS-31/cardiolipin complex inhibited cytochrome c peroxidase activity, which catalyses cardiolipin peroxidation and mitochondrial damage during ischaemia, by protecting the heme iron. The authors concluded that SS-31 protects mitochondrial cristae in ischaemic models (Birk et al., 2013). Later reviews describe stabilised respiratory supercomplexes and reduced reactive oxygen species, which remain interpretations of model data.
Main research areas
- Cardiolipin and cristae biology: binding, supercomplex stability and cytochrome c peroxidase activity.
- Bioenergetics: ATP production and ROS output under ischaemia-reperfusion and oxidative stress.
- Cardiac and skeletal muscle models: preclinical work on ischaemia-reperfusion and muscle function.
- Ageing and mitochondrial decline: restoration of mitochondrial morphology in aged tissues in rodent studies.
What published studies actually show
SS-31 has a much larger human record than most compounds in this series. On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg (FDA approval letter). A confirmatory trial is a condition of that accelerated approval (PubMed).
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula and mass are database-verifiable. |
| Binding studies | High-affinity cardiolipin binding and 1:1 stoichiometry in model membranes. |
| Animal studies | Protective bioenergetic effects in ischaemia, cardiac and ageing models. |
| Regulatory | One accelerated approval, for a pharmaceutical-grade product, in one indication and one jurisdiction. |
That approval is a regulatory fact about a specific medicine. It does not make research-grade SS-31 a medicine, and it does not establish effects in any other setting.
Scientific limitations and open questions
- The approval covers one indication, and accelerated approval requires confirmatory evidence of benefit.
- Trials in other indications have given mixed results and have not led to approval.
- Cardiolipin binding is shown in model systems; downstream effects in vivo remain interpretations.
- Approval of a pharmaceutical product does not apply to research-grade material.
- It is not authorised as a medicine in the EU.
Analytical and laboratory considerations
SS-31 is small and highly water-soluble, with no methionine or cysteine, so it is simpler to handle than larger peptides. Its D-Arg and Dmt residues mean that mass spectrometry should show 639.8 Da and chromatography should separate any L-isomer impurity, which has the same mass.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the SS-31 product page.
Sources and further reading
- Birk A.V. et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 24(8):1250-1261. PubMed
- Szeto H.H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. PMC full text
- FDA (2025). Forzinity (elamipretide) accelerated approval letter, NDA 215244. FDA · Elamipretide: First Approval (PubMed)
- PubChem compound record for elamipretide (CID 11764719). PubChem
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is SS-31?
What is the difference between SS-31 and elamipretide?
What is the sequence and molecular weight of SS-31?
How does SS-31 reach the mitochondria?
What is cardiolipin?
Is SS-31 an approved medicine?
How is SS-31 different from MOTS-c?
Keep reading
Related reading
SS-31
Current batches, formats and the COA for SS-31.
What is NAD+?
The coenzyme at the centre of mitochondrial energy research.
What is MOTS-c?
A mitochondrial-derived peptide linked to AMPK signalling.
Research-grade SS-31, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
